Jiangsu Nhwa Pharmaceutical Co Ltd (002262) - Net Assets

Latest as of March 2026: CN¥8.35 Billion CNY ≈ $1.22 Billion USD

Based on the latest financial reports, Jiangsu Nhwa Pharmaceutical Co Ltd (002262) has net assets worth CN¥8.35 Billion CNY (≈ $1.22 Billion USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥9.64 Billion ≈ $1.41 Billion USD) and total liabilities (CN¥1.30 Billion ≈ $189.81 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore how large is Jiangsu Nhwa Pharmaceutical Co Ltd's balance sheet for the complete picture of this company's asset base.

Key Net Assets Metrics

Metric	Value
Current Net Assets	CN¥8.35 Billion
% of Total Assets	86.55%
Annual Growth Rate	23.1%
5-Year Change	63.71%
10-Year Change	277.98%
Growth Volatility	26.69

Jiangsu Nhwa Pharmaceutical Co Ltd - Net Assets Trend (2005–2025)

This chart illustrates how Jiangsu Nhwa Pharmaceutical Co Ltd's net assets have evolved over time, based on quarterly financial data. Check Jiangsu Nhwa Pharmaceutical Co Ltd (002262) tangible net worth to evaluate the tangible quality of the company's equity base.

Annual Net Assets for Jiangsu Nhwa Pharmaceutical Co Ltd (2005–2025)

The table below shows the annual net assets of Jiangsu Nhwa Pharmaceutical Co Ltd from 2005 to 2025. For live valuation and market cap data, see 002262 market cap overview.

Year	Net Assets	Change
2025-12-31	CN¥8.03 Billion ≈ $1.17 Billion	+10.37%
2024-12-31	CN¥7.27 Billion ≈ $1.06 Billion	+13.47%
2023-12-31	CN¥6.41 Billion ≈ $938.00 Million	+14.80%
2022-12-31	CN¥5.58 Billion ≈ $817.07 Million	+13.87%
2021-12-31	CN¥4.90 Billion ≈ $717.57 Million	+19.44%
2020-12-31	CN¥4.11 Billion ≈ $600.76 Million	+13.89%
2019-12-31	CN¥3.60 Billion ≈ $527.50 Million	+21.86%
2018-12-31	CN¥2.96 Billion ≈ $432.87 Million	+20.19%
2017-12-31	CN¥2.46 Billion ≈ $360.17 Million	+15.89%
2016-12-31	CN¥2.12 Billion ≈ $310.80 Million	+16.23%
2015-12-31	CN¥1.83 Billion ≈ $267.39 Million	+72.54%
2014-12-31	CN¥1.06 Billion ≈ $154.97 Million	+26.65%
2013-12-31	CN¥836.21 Million ≈ $122.36 Million	+22.53%
2012-12-31	CN¥682.44 Million ≈ $99.86 Million	+22.74%
2011-12-31	CN¥556.01 Million ≈ $81.36 Million	+20.20%
2010-12-31	CN¥462.56 Million ≈ $67.69 Million	+16.81%
2009-12-31	CN¥396.00 Million ≈ $57.95 Million	+15.20%
2008-12-31	CN¥343.75 Million ≈ $50.30 Million	+125.58%
2007-12-31	CN¥152.39 Million ≈ $22.30 Million	+24.23%
2006-12-31	CN¥122.67 Million ≈ $17.95 Million	-2.44%
2005-12-31	CN¥125.74 Million ≈ $18.40 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Jiangsu Nhwa Pharmaceutical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have grown by 53173.1% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2025)

Component	Amount	Percentage
Retained Earnings	CN¥6.32 Billion	78.46%
Other Components	CN¥1.74 Billion	21.54%
Total Equity	CN¥8.06 Billion	100.00%

Jiangsu Nhwa Pharmaceutical Co Ltd Competitors by Market Cap

The table below lists competitors of Jiangsu Nhwa Pharmaceutical Co Ltd ranked by their market capitalization.

Company	Market Cap
Fujian Longking Co Ltd SHG:600388	$3.30 Billion
Glory View Technology Co. Ltd. A SHE:301396	$3.31 Billion
International Game Technology PLC NYSE:IGT	$3.31 Billion
TELEPERFORMANCE SE ADR F:RCF0	$3.31 Billion
Berner Kantonalbank AG SW:BEKN	$3.30 Billion
Energix Renewable Energies Ltd TA:ENRG	$3.30 Billion
Jiangxi Jovo Energy Co. Ltd SHG:605090	$3.30 Billion
Denali Therapeutics Inc NASDAQ:DNLI	$3.30 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Jiangsu Nhwa Pharmaceutical Co Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

From 2024 to 2025, total equity changed from 7,300,321,724 to 8,057,134,575, a change of 756,812,851 (10.4%).
Net income of 1,057,334,354 contributed positively to equity growth.
Dividend payments of 366,205,270 reduced retained earnings.
Other comprehensive income decreased equity by 660,570,588.
Other factors increased equity by 726,254,355.

Equity Change Factors (2024 to 2025)

Factor	Impact	Contribution
Net Income	CN¥1.06 Billion	+13.12%
Dividends Paid	CN¥366.21 Million	-4.55%
Other Comprehensive Income	CN¥-660.57 Million	-8.2%
Other Changes	CN¥726.25 Million	+9.01%
Total Change	CN¥-	10.37%

Book Value vs Market Value Analysis

This analysis compares Jiangsu Nhwa Pharmaceutical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 2.80x
The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
The price-to-book ratio has decreased from 70.95x to 2.80x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2005-12-31	CN¥0.31	CN¥22.23	x
2006-12-31	CN¥0.25	CN¥22.23	x
2007-12-31	CN¥0.22	CN¥22.23	x
2008-12-31	CN¥0.45	CN¥22.23	x
2009-12-31	CN¥0.45	CN¥22.23	x
2010-12-31	CN¥0.52	CN¥22.23	x
2011-12-31	CN¥0.63	CN¥22.23	x
2012-12-31	CN¥0.69	CN¥22.23	x
2013-12-31	CN¥0.85	CN¥22.23	x
2014-12-31	CN¥1.06	CN¥22.23	x
2015-12-31	CN¥1.80	CN¥22.23	x
2016-12-31	CN¥2.08	CN¥22.23	x
2017-12-31	CN¥2.43	CN¥22.23	x
2018-12-31	CN¥2.93	CN¥22.23	x
2019-12-31	CN¥3.58	CN¥22.23	x
2020-12-31	CN¥4.07	CN¥22.23	x
2021-12-31	CN¥4.88	CN¥22.23	x
2022-12-31	CN¥5.58	CN¥22.23	x
2023-12-31	CN¥6.39	CN¥22.23	x
2024-12-31	CN¥7.21	CN¥22.23	x
2025-12-31	CN¥7.93	CN¥22.23	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Jiangsu Nhwa Pharmaceutical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 13.12%
The company shows good efficiency in utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 17.89%
• Asset Turnover: 0.64x
• Equity Multiplier: 1.14x
Recent ROE (13.12%) is below the historical average (16.58%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2005	14.43%	2.63%	1.32x	4.14x	CN¥5.16 Million
2006	14.69%	2.44%	1.38x	4.36x	CN¥5.42 Million
2007	18.32%	3.31%	1.35x	4.10x	CN¥12.11 Million
2008	12.08%	4.27%	1.31x	2.16x	CN¥7.00 Million
2009	13.98%	4.92%	1.42x	2.00x	CN¥15.56 Million
2010	16.67%	5.88%	1.36x	2.08x	CN¥30.58 Million
2011	19.12%	6.65%	1.45x	1.98x	CN¥50.40 Million
2012	20.53%	7.05%	1.47x	1.98x	CN¥71.65 Million
2013	21.03%	7.88%	1.43x	1.87x	CN¥92.45 Million
2014	21.40%	8.93%	1.30x	1.84x	CN¥118.94 Million
2015	14.24%	9.34%	1.08x	1.41x	CN¥76.88 Million
2016	14.78%	10.26%	1.01x	1.42x	CN¥100.18 Million
2017	16.09%	11.63%	1.03x	1.35x	CN¥149.40 Million
2018	17.74%	13.60%	0.96x	1.36x	CN¥228.90 Million
2019	18.32%	15.99%	0.99x	1.16x	CN¥301.24 Million
2020	17.68%	21.68%	0.70x	1.17x	CN¥316.52 Million
2021	16.21%	20.27%	0.69x	1.16x	CN¥305.71 Million
2022	16.02%	20.95%	0.66x	1.15x	CN¥338.56 Million
2023	16.12%	20.57%	0.69x	1.14x	CN¥393.50 Million
2024	15.66%	20.07%	0.68x	1.16x	CN¥413.53 Million
2025	13.12%	17.89%	0.64x	1.14x	CN¥251.62 Million

Industry Comparison

This section compares Jiangsu Nhwa Pharmaceutical Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

Industry: Drug Manufacturers - Specialty & Generic
Average net assets among peers: $2,536,896,341
Average return on equity (ROE) among peers: 9.73%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Jiangsu Nhwa Pharmaceutical Co Ltd (002262)	CN¥8.35 Billion	14.43%	0.16x	$3.30 Billion
Shenzhen Neptunus Bioengineering Co Ltd (000078)	$692.59 Million	2.04%	3.57x	$642.98 Million
Anhui Fengyuan Pharmaceutical Co Ltd (000153)	$1.15 Billion	3.57%	0.95x	$376.71 Million
Shan Dong Dong-E E-Jiao Co Ltd (000423)	$377.25 Million	11.95%	0.42x	$5.22 Billion
Livzon Pharmaceutical Group Inc (000513)	$973.90 Million	0.17%	0.60x	$2.67 Billion
Wedge Industrial Co Ltd (000534)	$760.85 Million	18.95%	0.28x	$1.86 Billion
Yunnan Baiyao Group Co Ltd (000538)	$7.04 Billion	22.50%	0.52x	$13.65 Billion
Hainan Haiyao Co Ltd (000566)	$292.94 Million	7.42%	0.73x	$1.08 Billion
Tus Pharmaceutical Group Co Ltd (000590)	$280.91 Million	1.46%	1.58x	$299.61 Million
Northeast Pharmaceutical Group Co Ltd (000597)	$4.71 Billion	7.43%	1.93x	$964.78 Million
Jilin Aodong Pharmaceutical Group Co Ltd (000623)	$9.09 Billion	21.79%	0.11x	$3.21 Billion

About Jiangsu Nhwa Pharmaceutical Co Ltd

SHE:002262 China Drug Manufacturers - Specialty & Generic

Market Cap

$3.30 Billion

CN¥22.58 Billion CNY

Market Cap Rank

#4589 Global

#733 in China

Share Price

CN¥22.23

Change (1 day)

+0.59%

52-Week Range

CN¥18.23 - CN¥28.92

All Time High

CN¥31.19